Year: 2026

— Highly selective SIK2 inhibitors demonstrate dual mechanism of suppressing inflammation while promoting pro-resolution and tissue repair pathways —

BOSTON, Mass. — April 16, 2026 — Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a drug discovery company developing breakthrough medicines through AI-enhanced computational chemistry, today announced that it is presenting new mechanistic data on its novel salt-inducible kinase 2 (SIK2) inhibitor program at IMMUNOLOGY2026™, the 109^th annual meeting of the American Association of Immunologists (AAI), taking place April 15–19, 2026, in Boston, Massachusetts.

 

Salt-inducible kinases (SIKs) comprise three closely related isoforms (SIK1, SIK2, and SIK3) that function as key signaling nodes in myeloid cells, integrating pathogen- and damage-associated cues to drive inflammation. Among these, SIK2 plays a critical role in regulating proinflammatory gene expression. Using structure-based drug design, Nimbus has developed highly selective SIK2 inhibitors with greater than 300-fold selectivity over the SIK1 and SIK3 isoforms. Preclinical data demonstrate that selective inhibition of SIK2 drives a dual pharmacological profile in myeloid cells and mice, suppressing proinflammatory cytokines while simultaneously promoting pro-resolution and tissue repair signals, a mechanistic profile distinct from SIK3 and JAK1 inhibition.

 

Presentation Details:

Abstract Title: Selective SIK2 Inhibitors Suppress Proinflammatory Responses While Upregulating Pro-Resolution Signals in Stimulated Myeloid Cells and Mice

Session: Therapeutics for Autoimmune Diseases I

Date: Thursday, April 16, 2026

Time: 2:30 p.m. – 3:30 p.m. ET

Poster Board Number: 556

Session Location: Exhibit Hall

Presenter: Leon Collis, Ph.D.

 

The poster will be available on the Nimbus website here.

 

These findings build on data presented earlier this year at the 21^st Congress of the European Crohn’s and Colitis Organisation (ECCO), where Nimbus reported robust efficacy and protection of the mucosal barrier in mouse colitis models, and anti-inflammatory and tissue repair activity in human ex vivo systems. The IMMUNOLOGY2026 presentation extends that work with a deeper mechanistic characterization, demonstrating that Nimbus’ highly selective SIK2 inhibitors simultaneously downregulate multiple proinflammatory cytokines, including TNFα, IL-23, and IL-6, while upregulating pro-resolution and tissue repair factors, including IL-10. Importantly, this dual effect was not observed with SIK3 inhibition, which instead elevates IL-23 and IL-12, key drivers of inflammatory disease, further highlighting the critical importance of isoform selectivity.

“These data continue to strengthen our conviction that SIK2-selective inhibition is required for this dual mechanism of dampening inflammation and promoting tissue repair,” said Peter Tummino, Ph.D., President of Research and Development at Nimbus. “This distinct profile supports SIK2 inhibition as a differentiated oral therapeutic approach for inflammatory bowel disease and other chronic inflammatory diseases.”

 

Nimbus’ SIK2 program is advancing through investigational new drug (IND)-enabling studies toward first-in-human evaluation in inflammatory and autoimmune diseases.

 

About Nimbus Therapeutics

Nimbus Therapeutics is a structure-based drug discovery company developing breakthrough small molecule medicines through AI-enhanced computational chemistry. Nimbus pursues well-validated but difficult-to-drug targets with high potential to transform patients’ lives. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches.

Nimbus’ pipeline includes NDI-219216, a Werner syndrome helicase (WRN) inhibitor in Phase 1/2 clinical development for microsatellite instability high (MSI-H) tumors, a salt-inducible kinase 2 (SIK2) inhibitor program advancing toward first-in-human studies for inflammatory and autoimmune diseases, and multiple preclinical programs across oncology, immunology, and metabolic diseases. The company is headquartered in Boston, Mass. To learn more about Nimbus, please visit www.nimbustx.com.

 

Media Contact

Cindy Fung, Ph.D.

Nimbus Therapeutics

cindy.fung@nimbustx.com

— New collaboration follows previous Lilly and Nimbus AMPK research collaboration in cardiometabolic disease —

BOSTON, Mass. – January 6, 2026 – Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it has entered into a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (“Lilly”) to develop a novel oral treatment for obesity and other metabolic diseases.

This new collaboration follows the previous collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases. The companies will now apply Nimbus’ computational chemistry and structure-based drug design approach to an early-stage, small molecule discovery program addressing a significant unmet need in obesity.

“We are pleased to deepen our collaboration with Nimbus, a team that has demonstrated exceptional ability to tackle complex drug discovery challenges,” said Ruth Gimeno, Group Vice President, Diabetes and Metabolic Research and Development at Lilly. “Working together to develop this novel obesity therapy represents an important addition to Lilly’s efforts to advance innovative treatment options for patients with metabolic disorders.”

“At Nimbus, computational scientists, medicinal chemists, pharmacologists and translational biologists work together to integrate AI-driven predictive models with structure-based design to develop novel small molecules with best-in-class potential. This integration has enabled us to consistently deliver optimized clinical candidates for difficult-to-drug targets,” said Peter J. Tummino, Ph.D., President of Research and Development at Nimbus. “We are excited to collaborate with Lilly on another program, combining our discovery capabilities with their metabolic disease expertise to bring a much-needed new treatment to people with obesity and make a meaningful difference in their lives.”

Under the terms of the collaboration, Nimbus is eligible to receive upfront and near-term milestone payments totaling $55 million, with eligibility to receive up to approximately $1.3 billion in total including development, commercial, and sales milestone payments, as well as tiered royalties on global net sales.

About Nimbus Therapeutics

Nimbus Therapeutics is a structure-based drug discovery company developing breakthrough small molecule medicines through AI-enhanced computational chemistry. Nimbus pursues well-validated but difficult-to-drug targets with high potential to transform patients’ lives. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches.

Nimbus’ pipeline includes NDI-219216, a Werner syndrome helicase (WRN) inhibitor in Phase 1/2 development for microsatellite instability high (MSI-H) tumors, a salt-inducible kinase 2 (SIK2) inhibitor advancing toward first-in-human studies for inflammatory and autoimmune diseases, and multiple preclinical programs in oncology, immunology, and metabolic diseases. The company is headquartered in Boston, Mass. To learn more about Nimbus, please visit www.nimbustx.com.

 

Media Contact:

Cindy Fung, PhD

Nimbus Therapeutics

cindy.fung@nimbustx.com